

For Immediate Release
For Further Information Contact:
Andrew Fisher at (202) 483-7000
Email: Afisher@unither.com

**REMODULIN® OVERVIEW PUBLISHED IN
JOURNAL OF EXPERT OPINION OF INVESTIGATIONAL DRUGS**

Research Triangle Park, NC, November 26, 2002: United Therapeutics Corporation (NASDAQ:UTHR) today announced that the journal *EXPERT OPINION OF INVESTIGATIONAL DRUGS* published “Treprostinil Therapy for Pulmonary Hypertension”, an article by Drs. Evelyn Horn and Robyn Barst of the Department of Medicine and Pediatrics at the New York Presbyterian Pulmonary Hypertension Center, in its current issue ((2002) 11(11):1615-1622).

In their summary opinion, Drs. Horn and Barst provide a comprehensive overview of Remodulin (treprostinil sodium) Injection therapy, with a detailed summary of the pivotal trial data. Drs. Horn and Barst also describe the favorable relationship between the dose of Remodulin and the improvement achieved. A similar analysis is provided that relates the magnitude of benefit to disease severity. In closing, Drs. Horn and Barst provide their opinion as to the practical indications for the use of Remodulin in relation to other available treatment options with particular regard to the risk/benefit profile of each therapy.

Remodulin received United States Food and Drug Administration approval on May 21, 2002, Canadian Therapeutic Products Directorate approval on October 4, 2002 and approval from the Israeli Ministry of Health on October 31, 2002. United Therapeutics has submitted marketing applications for Remodulin in France, Switzerland and Australia, with additional European filings to follow approval in France. In clinical trials, the most common side effects reported with Remodulin therapy included infusion site pain (85%) and infusion site reaction (83%). Other adverse events included headache (27%), diarrhea (25%), nausea (22%), rash (14%), jaw pain (13%), vasodilatation (11%), dizziness (9%), edema (9%), pruritus (8%) and hypotension (4%). Remodulin should be used only by clinicians experienced in the diagnosis and treatment of PAH.

United Therapeutics is a biotechnology company focused on combating chronic and life-threatening cardiovascular, infectious and oncologic diseases with unique therapeutic products.

* * *